en.Wedoany.com Reported - On August 10, BeiGene and U.S. biotechnology company Revolution Medicines disclosed a clinical development and regional commercialization collaboration. The two parties will evaluate combination regimens involving certain of BeiGene's clinical-stage oncology candidates and Revolution Medicines' four RAS(ON) inhibitors; BeiGene will also obtain exclusive development and commercialization rights, or exclusive commercialization rights depending on the specific market, for these four drugs in select Asian markets.
The four candidates included in the collaboration are daraxonrasib, a RAS(ON) multi-selective inhibitor; zoldonrasib, a RAS(ON) G12D selective inhibitor; elironrasib, a RAS(ON) G12C selective inhibitor; and RMC-5127, a RAS(ON) G12V selective inhibitor, covering multiple RAS mutation types associated with tumorigenesis.
The first wave of combination therapy studies will pair BeiGene's MTA-cooperative PRMT5 inhibitor BGB-58067 and EGFR×MET×MET trispecific antibody BG-T187 with daraxonrasib or zoldonrasib, respectively. These studies target RAS-driven cancers, and future combination regimens may also include Revolution Medicines' other clinical-stage RAS(ON) inhibitors.
In terms of regional licensing, Revolution Medicines is eligible to receive development milestone payments, sales milestone payments, and tiered royalties calculated on net sales in the collaboration territories. Japan and South Korea are not included in this licensing scope, and Revolution Medicines retains development and commercialization rights outside the licensed territories. The announcement from the two parties did not specify the upfront payment, milestone payment caps, royalty rates, or the specific list of licensed markets.
Under the collaboration arrangement, BeiGene will also fund and conduct a global registrational Phase 3 clinical study for one of the RAS(ON) inhibitors, while Revolution Medicines will continue to advance other global registrational studies in its portfolio. The parties have not yet disclosed which specific candidate will be the subject of the Phase 3 study funded by BeiGene.
As of August 5, all four candidates remain in clinical development and have not been approved for commercial use. Among them, the New Drug Application for daraxonrasib in previously treated metastatic pancreatic cancer has been accepted by the U.S. Food and Drug Administration; zoldonrasib has multiple global Phase 3 studies underway; a global Phase 3 study for elironrasib is planned to initiate in the fourth quarter of 2026; and RMC-5127 is undergoing first-in-human clinical trials, with a recommended Phase 2 dose expected to be determined in the second half of 2026.
